Search for: "Fibrogen, Inc."
Results 1 - 7
of 7
Sorted by Relevance
|
Sort by Date
5 May 2020, 12:35 pm
(“Otsuka”) to revoke 6 patents held by FibroGen Inc. [read post]
28 Apr 2020, 11:46 pm
by Olivia Henry and Nicholas Michelmore On 20 April 2020, Arnold LJ (sitting as a High Court Judge) gave judgment in the case between FibroGen Inc and Astellas Pharma Inc (together the “Claimants”), and Akebia Therapeutics Inc and Otsuka Pharmaceutical Company Limited (together the “Defendants”) which concerned six patents owned by FibroGen and exclusively licensed to Astellas (the “Patents”). [read post]
8 Sep 2021, 7:50 am
In undoubtedly one of the most important decisions of the year so far, on 24 August 2021, the English Court of Appeal handed down its judgment in FibroGen v Akebia (FibroGen Inc v Akebia Therapeutics Inc [2021] EWCA Civ 1279), partially allowing FibroGen’s appeal, and so finding one of the ‘Family A’ patents, EP 823, valid and infringed. [read post]
3 May 2020, 2:25 pm
Gilead Sciences Inc. [read post]
17 May 2020, 2:57 am
Public.Resource.Org, Inc. | [GuestPost] The Nadorcott Case - Shifting the plant variety paradigm from a proprietary to a liability rule | In memoriam: Dr. [read post]
13 Jul 2021, 4:00 am
In contrast, in Akebia Therapeutics, Inc. v. [read post]
3 Nov 2023, 7:15 am
The present case started as a claim for infringement brought by Astellas Pharma Inc (“Astellas”) against Teva and Sandoz (the “Defendants”). [read post]
